Predicting deadly outcomes in aggressive breast cancer using advanced technology
Early prediction of lethal phenotypes in triple negative breast cancer using multiscale, multi-modality platforms
This study is working on new ways to better predict which patients with triple negative breast cancer might face the most serious outcomes, so that doctors can create more personalized treatment plans to help improve their chances of survival.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11051889 on NIH RePORTER |
What this research studies
This research focuses on improving the prediction of lethal outcomes in patients with triple negative breast cancer (TNBC), which is known for its aggressive nature and poor prognosis. By utilizing a multi-scale and multi-modality approach, the study aims to develop new tools that can accurately identify patients at high risk of death from this disease. The methodology involves advanced artificial intelligence techniques and Bayesian modeling to analyze various patient data and treatment responses. This could lead to more personalized treatment strategies and better outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple negative breast cancer, particularly those undergoing adjuvant chemotherapy.
Not a fit: Patients with non-triple negative breast cancer or those not receiving chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of lethal outcomes in TNBC, allowing for tailored treatment plans that could improve survival rates.
How similar studies have performed: While there have been studies focusing on TNBC, this approach utilizing advanced AI and Bayesian models is relatively novel and has not been extensively tested.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Badve, Sunil S. — Emory University
- Study coordinator: Badve, Sunil S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.